Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto

An oncolytic adenovirus, bispecific technology, applied in the field of human cancer treatment, oncolytic adenovirus vector, can solve the problems of unpredictable cancer therapy, inefficiency, unsafety, etc., to reduce tumor immunosuppression and enhance treatment effect, effect of preventing adverse events

Pending Publication Date: 2017-11-28
TILT BIOTHERAPEUTICS OY
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The purpose of the present invention is to provide a simple method and tool for overcoming the above problems of inefficient, unsafe and unpredictable cancer therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
  • Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
  • Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0130] Materials and Methods

[0131] B16-OVA animal model: B16 cells expressing ovalbumin (B16-OVA) were maintained in RPMI, 10% FBS, 5 mg / ml G418, 20 mM L-glutamine, 1×Pen / Strep solution (GIBCO). C57BL / 6 immunocompetent female mice aged 4-7 weeks were subcutaneously implanted with 2.5×10 in 50 μl RPMI, 0% FBS on the right side 5 B16-OVA cells, one tumor per mouse. Approximately ten days after tumor implantation (approximately 3 mm minimum diameter when tumors became injectable), mice were grouped and treated with 50 μl PBS or 1 × 10 in 50 μl PBS for six consecutive days in some experiments. 9 Intratumoral injection of viral particles (VP) of an oncolytic adenovirus was performed. In other experiments, three injections were performed on days 0, 2 and 4. Since murine cells do not tolerate human adenovirus, multiple intratumoral virus injections were used to mimic viral replication-induced inflammation (Blair et al., 1989).

[0132] Adoptive transfer: On the first day of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.

Description

field of invention [0001] The present invention relates to the fields of life science and medicine. In particular, the invention relates to the treatment of cancer in humans. More specifically, the present invention relates to oncolytic adenoviral vectors encoding bispecific monoclonal antibodies. Furthermore, the present invention relates to methods and uses utilizing oncolytic adenoviral vectors and in conjunction with adoptive cell therapy. Background of the invention [0002] New therapies for cancer treatment are continuously being developed. Adoptive cell therapy (ACT) is an effective approach for the treatment of cancer, but also for the treatment of other diseases such as infection and graft versus host disease. Adoptive cell transfer (Adoptive cell transfer) is the passive transplantation of cells grown in vitro (most commonly immune-derived cells) into the host, with the purpose of transferring the immunological function and characteristics of the graft. Adopti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/861A61K35/761A61K48/00A61P35/00
CPCA61K35/761A61K48/0025A61K48/005C12N15/86A61K2039/585C12N2710/10332C12N2710/10343C07K16/28C07K16/2809C07K16/3092C07K2317/31C07K2317/622C07K16/30A61P35/00A61P35/02A61P43/00C07K16/2821C12N2710/00044C12N2710/00045C12N2710/10033
Inventor A.赫明基S.帕尔维艾宁S.泰蒂宁I.利卡宁M.休雷拉
Owner TILT BIOTHERAPEUTICS OY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com